Cancer‐associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma
. Gronlund B, Dehn H, Høgdall CK, Engelholm SA, Jørgensen M, Nørgaard‐Pedersen B, Høgdall EVS. Cancer‐associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma. Int J Gynecol Cancer 2005;15:836–843. The aim was to examine the value of the...
Gespeichert in:
| Veröffentlicht in: | International journal of gynecological cancer 2005-09, Vol.15 (5), p.836-843 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 843 |
|---|---|
| container_issue | 5 |
| container_start_page | 836 |
| container_title | International journal of gynecological cancer |
| container_volume | 15 |
| creator | GRONLUND, B. DEHN, H. HØGdall, C.K. ENGELHOLM, S.A. JØRGENSEN, M. NØRGAARD‐PEDERSEN, B. HØGDALL, E.V.S. |
| description | . Gronlund B, Dehn H, Høgdall CK, Engelholm SA, Jørgensen M, Nørgaard‐Pedersen B, Høgdall EVS. Cancer‐associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma. Int J Gynecol Cancer 2005;15:836–843.
The aim was to examine the value of the pretherapeutic serum cancer‐associated serum antigen (CASA) level as a prognostic factor for survival in patients with recurrent epithelial ovarian carcinoma. Serum levels of CASA and cancer antigen (CA)125 were prospectively determined in 70 consecutive patients with recurrent ovarian cancer before the start of second‐line chemotherapy. Univariate and multivariate analyses of survival were performed. The median level of serum CASA was 6.5 U/mL (range: 0.2–1437 U/mL). Univariate analysis showed that patients with a CASA level >10.0 U/mL had significantly shorter survival than patients with CASA level ≤10.0 U/mL (P= 0.002). Using different CASA cutoff levels (6.0, 6.5, and 10.0 U/mL), multivariate Cox analyses identified CASA as an independent prognostic factor for survival at every cutoff level. The strongest prognostic function for CASA was found at a cutoff level of 10.0 U/mL (>10 vs ≤10 U/mL; hazard ratio, 2.7; 95% confidence interval, 1.6–4.7; P < 0.001). The pretreatment CA125 level was not found to be significantly associated with survival by any of the cutoffs (35, 65, 132, and 339 U/mL). A pretreatment elevated level of the tumor marker CASA is an adverse prognostic factor for survival in patients with ovarian cancer relapse. |
| doi_str_mv | 10.1111/j.1525-1438.2005.00145.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68606123</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20245318</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4420-af238ab23fed77dbaf060cf936d588e83604db0cde561b692b8a08bf8af47b63</originalsourceid><addsrcrecordid>eNqNkcFu1DAQhiMEoqXwCsgnbgljx0kcxAWtSimqxKUHbtbEmXS9eJ3FTnbbEzwCz8iT4LArOIKlkWfs_x-P_GUZ41DwtF5vCl6JKueyVIUAqAoALqvi_lF2_uficcpBqly1_PNZ9izGDQC0Atqn2RmveSNFWZ5n31boDYWf339gjKOxOFHPIoV5y9BP9o48c7Qn94Yh82NK2C6Md36MkzXM-t4anMbAhhRxDnu7R5eO2Q4nS36K7GCnNQtk5hBSzcY9BoueGQzG-nGLz7MnA7pIL077RXb7_vJ29SG_-XR1vXp3kxspBeQ4iFJhJ8qB-qbpOxygBjO0Zd1XSpEqa5B9B6anquZd3YpOIahuUDjIpqvLi-zVsW2a_utMcdJbGw05h57GOepa1VDz9CP_EgoQsiq5SkJ1FJowxhho0LtgtxgeNAe9QNIbvbDQCwu9QNK_Ien7ZH15emPuttT_NZ6oJIE8Cg6jmyjEL24-UNBrQjetU5vEsWqafGkKbaryFAKS7e3JZh09_Pc8-vrjVUrKXxvqs-o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20245318</pqid></control><display><type>article</type><title>Cancer‐associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>GRONLUND, B. ; DEHN, H. ; HØGdall, C.K. ; ENGELHOLM, S.A. ; JØRGENSEN, M. ; NØRGAARD‐PEDERSEN, B. ; HØGDALL, E.V.S.</creator><creatorcontrib>GRONLUND, B. ; DEHN, H. ; HØGdall, C.K. ; ENGELHOLM, S.A. ; JØRGENSEN, M. ; NØRGAARD‐PEDERSEN, B. ; HØGDALL, E.V.S.</creatorcontrib><description>. Gronlund B, Dehn H, Høgdall CK, Engelholm SA, Jørgensen M, Nørgaard‐Pedersen B, Høgdall EVS. Cancer‐associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma. Int J Gynecol Cancer 2005;15:836–843.
The aim was to examine the value of the pretherapeutic serum cancer‐associated serum antigen (CASA) level as a prognostic factor for survival in patients with recurrent epithelial ovarian carcinoma. Serum levels of CASA and cancer antigen (CA)125 were prospectively determined in 70 consecutive patients with recurrent ovarian cancer before the start of second‐line chemotherapy. Univariate and multivariate analyses of survival were performed. The median level of serum CASA was 6.5 U/mL (range: 0.2–1437 U/mL). Univariate analysis showed that patients with a CASA level >10.0 U/mL had significantly shorter survival than patients with CASA level ≤10.0 U/mL (P= 0.002). Using different CASA cutoff levels (6.0, 6.5, and 10.0 U/mL), multivariate Cox analyses identified CASA as an independent prognostic factor for survival at every cutoff level. The strongest prognostic function for CASA was found at a cutoff level of 10.0 U/mL (>10 vs ≤10 U/mL; hazard ratio, 2.7; 95% confidence interval, 1.6–4.7; P < 0.001). The pretreatment CA125 level was not found to be significantly associated with survival by any of the cutoffs (35, 65, 132, and 339 U/mL). A pretreatment elevated level of the tumor marker CASA is an adverse prognostic factor for survival in patients with ovarian cancer relapse.</description><identifier>ISSN: 1048-891X</identifier><identifier>EISSN: 1525-1438</identifier><identifier>DOI: 10.1111/j.1525-1438.2005.00145.x</identifier><identifier>PMID: 16174233</identifier><language>eng</language><publisher>Oxford, UK; Malden, USA: Blackwell Science Inc</publisher><subject>Adult ; Aged ; Antigens, Neoplasm - blood ; CA-125 Antigen - blood ; CA125 ; CASA ; epithelial ovarian cancer ; Female ; Humans ; Middle Aged ; Multivariate Analysis ; Neoplasm Recurrence, Local - blood ; Neoplasm Recurrence, Local - diagnosis ; Neoplasm Recurrence, Local - pathology ; Ovarian Neoplasms - blood ; Ovarian Neoplasms - diagnosis ; Ovarian Neoplasms - pathology ; Prognosis ; prognostic factors ; relapse ; Survival Rate</subject><ispartof>International journal of gynecological cancer, 2005-09, Vol.15 (5), p.836-843</ispartof><rights>Copyright © 2005 Blackwell Publishing Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4420-af238ab23fed77dbaf060cf936d588e83604db0cde561b692b8a08bf8af47b63</citedby><cites>FETCH-LOGICAL-c4420-af238ab23fed77dbaf060cf936d588e83604db0cde561b692b8a08bf8af47b63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1525-1438.2005.00145.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1525-1438.2005.00145.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16174233$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GRONLUND, B.</creatorcontrib><creatorcontrib>DEHN, H.</creatorcontrib><creatorcontrib>HØGdall, C.K.</creatorcontrib><creatorcontrib>ENGELHOLM, S.A.</creatorcontrib><creatorcontrib>JØRGENSEN, M.</creatorcontrib><creatorcontrib>NØRGAARD‐PEDERSEN, B.</creatorcontrib><creatorcontrib>HØGDALL, E.V.S.</creatorcontrib><title>Cancer‐associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma</title><title>International journal of gynecological cancer</title><addtitle>Int J Gynecol Cancer</addtitle><description>. Gronlund B, Dehn H, Høgdall CK, Engelholm SA, Jørgensen M, Nørgaard‐Pedersen B, Høgdall EVS. Cancer‐associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma. Int J Gynecol Cancer 2005;15:836–843.
The aim was to examine the value of the pretherapeutic serum cancer‐associated serum antigen (CASA) level as a prognostic factor for survival in patients with recurrent epithelial ovarian carcinoma. Serum levels of CASA and cancer antigen (CA)125 were prospectively determined in 70 consecutive patients with recurrent ovarian cancer before the start of second‐line chemotherapy. Univariate and multivariate analyses of survival were performed. The median level of serum CASA was 6.5 U/mL (range: 0.2–1437 U/mL). Univariate analysis showed that patients with a CASA level >10.0 U/mL had significantly shorter survival than patients with CASA level ≤10.0 U/mL (P= 0.002). Using different CASA cutoff levels (6.0, 6.5, and 10.0 U/mL), multivariate Cox analyses identified CASA as an independent prognostic factor for survival at every cutoff level. The strongest prognostic function for CASA was found at a cutoff level of 10.0 U/mL (>10 vs ≤10 U/mL; hazard ratio, 2.7; 95% confidence interval, 1.6–4.7; P < 0.001). The pretreatment CA125 level was not found to be significantly associated with survival by any of the cutoffs (35, 65, 132, and 339 U/mL). A pretreatment elevated level of the tumor marker CASA is an adverse prognostic factor for survival in patients with ovarian cancer relapse.</description><subject>Adult</subject><subject>Aged</subject><subject>Antigens, Neoplasm - blood</subject><subject>CA-125 Antigen - blood</subject><subject>CA125</subject><subject>CASA</subject><subject>epithelial ovarian cancer</subject><subject>Female</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Recurrence, Local - blood</subject><subject>Neoplasm Recurrence, Local - diagnosis</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Ovarian Neoplasms - blood</subject><subject>Ovarian Neoplasms - diagnosis</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Prognosis</subject><subject>prognostic factors</subject><subject>relapse</subject><subject>Survival Rate</subject><issn>1048-891X</issn><issn>1525-1438</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkcFu1DAQhiMEoqXwCsgnbgljx0kcxAWtSimqxKUHbtbEmXS9eJ3FTnbbEzwCz8iT4LArOIKlkWfs_x-P_GUZ41DwtF5vCl6JKueyVIUAqAoALqvi_lF2_uficcpBqly1_PNZ9izGDQC0Atqn2RmveSNFWZ5n31boDYWf339gjKOxOFHPIoV5y9BP9o48c7Qn94Yh82NK2C6Md36MkzXM-t4anMbAhhRxDnu7R5eO2Q4nS36K7GCnNQtk5hBSzcY9BoueGQzG-nGLz7MnA7pIL077RXb7_vJ29SG_-XR1vXp3kxspBeQ4iFJhJ8qB-qbpOxygBjO0Zd1XSpEqa5B9B6anquZd3YpOIahuUDjIpqvLi-zVsW2a_utMcdJbGw05h57GOepa1VDz9CP_EgoQsiq5SkJ1FJowxhho0LtgtxgeNAe9QNIbvbDQCwu9QNK_Ien7ZH15emPuttT_NZ6oJIE8Cg6jmyjEL24-UNBrQjetU5vEsWqafGkKbaryFAKS7e3JZh09_Pc8-vrjVUrKXxvqs-o</recordid><startdate>200509</startdate><enddate>200509</enddate><creator>GRONLUND, B.</creator><creator>DEHN, H.</creator><creator>HØGdall, C.K.</creator><creator>ENGELHOLM, S.A.</creator><creator>JØRGENSEN, M.</creator><creator>NØRGAARD‐PEDERSEN, B.</creator><creator>HØGDALL, E.V.S.</creator><general>Blackwell Science Inc</general><general>Copyright Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>200509</creationdate><title>Cancer‐associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma</title><author>GRONLUND, B. ; DEHN, H. ; HØGdall, C.K. ; ENGELHOLM, S.A. ; JØRGENSEN, M. ; NØRGAARD‐PEDERSEN, B. ; HØGDALL, E.V.S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4420-af238ab23fed77dbaf060cf936d588e83604db0cde561b692b8a08bf8af47b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antigens, Neoplasm - blood</topic><topic>CA-125 Antigen - blood</topic><topic>CA125</topic><topic>CASA</topic><topic>epithelial ovarian cancer</topic><topic>Female</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Recurrence, Local - blood</topic><topic>Neoplasm Recurrence, Local - diagnosis</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Ovarian Neoplasms - blood</topic><topic>Ovarian Neoplasms - diagnosis</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Prognosis</topic><topic>prognostic factors</topic><topic>relapse</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GRONLUND, B.</creatorcontrib><creatorcontrib>DEHN, H.</creatorcontrib><creatorcontrib>HØGdall, C.K.</creatorcontrib><creatorcontrib>ENGELHOLM, S.A.</creatorcontrib><creatorcontrib>JØRGENSEN, M.</creatorcontrib><creatorcontrib>NØRGAARD‐PEDERSEN, B.</creatorcontrib><creatorcontrib>HØGDALL, E.V.S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of gynecological cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GRONLUND, B.</au><au>DEHN, H.</au><au>HØGdall, C.K.</au><au>ENGELHOLM, S.A.</au><au>JØRGENSEN, M.</au><au>NØRGAARD‐PEDERSEN, B.</au><au>HØGDALL, E.V.S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cancer‐associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma</atitle><jtitle>International journal of gynecological cancer</jtitle><addtitle>Int J Gynecol Cancer</addtitle><date>2005-09</date><risdate>2005</risdate><volume>15</volume><issue>5</issue><spage>836</spage><epage>843</epage><pages>836-843</pages><issn>1048-891X</issn><eissn>1525-1438</eissn><abstract>. Gronlund B, Dehn H, Høgdall CK, Engelholm SA, Jørgensen M, Nørgaard‐Pedersen B, Høgdall EVS. Cancer‐associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma. Int J Gynecol Cancer 2005;15:836–843.
The aim was to examine the value of the pretherapeutic serum cancer‐associated serum antigen (CASA) level as a prognostic factor for survival in patients with recurrent epithelial ovarian carcinoma. Serum levels of CASA and cancer antigen (CA)125 were prospectively determined in 70 consecutive patients with recurrent ovarian cancer before the start of second‐line chemotherapy. Univariate and multivariate analyses of survival were performed. The median level of serum CASA was 6.5 U/mL (range: 0.2–1437 U/mL). Univariate analysis showed that patients with a CASA level >10.0 U/mL had significantly shorter survival than patients with CASA level ≤10.0 U/mL (P= 0.002). Using different CASA cutoff levels (6.0, 6.5, and 10.0 U/mL), multivariate Cox analyses identified CASA as an independent prognostic factor for survival at every cutoff level. The strongest prognostic function for CASA was found at a cutoff level of 10.0 U/mL (>10 vs ≤10 U/mL; hazard ratio, 2.7; 95% confidence interval, 1.6–4.7; P < 0.001). The pretreatment CA125 level was not found to be significantly associated with survival by any of the cutoffs (35, 65, 132, and 339 U/mL). A pretreatment elevated level of the tumor marker CASA is an adverse prognostic factor for survival in patients with ovarian cancer relapse.</abstract><cop>Oxford, UK; Malden, USA</cop><pub>Blackwell Science Inc</pub><pmid>16174233</pmid><doi>10.1111/j.1525-1438.2005.00145.x</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1048-891X |
| ispartof | International journal of gynecological cancer, 2005-09, Vol.15 (5), p.836-843 |
| issn | 1048-891X 1525-1438 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68606123 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged Antigens, Neoplasm - blood CA-125 Antigen - blood CA125 CASA epithelial ovarian cancer Female Humans Middle Aged Multivariate Analysis Neoplasm Recurrence, Local - blood Neoplasm Recurrence, Local - diagnosis Neoplasm Recurrence, Local - pathology Ovarian Neoplasms - blood Ovarian Neoplasms - diagnosis Ovarian Neoplasms - pathology Prognosis prognostic factors relapse Survival Rate |
| title | Cancer‐associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T18%3A54%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cancer%E2%80%90associated%20serum%20antigen%20level:%20a%20novel%20prognostic%20indicator%20for%20survival%20in%20patients%20with%20recurrent%20ovarian%20carcinoma&rft.jtitle=International%20journal%20of%20gynecological%20cancer&rft.au=GRONLUND,%20B.&rft.date=2005-09&rft.volume=15&rft.issue=5&rft.spage=836&rft.epage=843&rft.pages=836-843&rft.issn=1048-891X&rft.eissn=1525-1438&rft_id=info:doi/10.1111/j.1525-1438.2005.00145.x&rft_dat=%3Cproquest_cross%3E20245318%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20245318&rft_id=info:pmid/16174233&rfr_iscdi=true |